['HIV-ANTIVIRAL AGENTS', 'NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS:', '', 'APPROPRIATE DOSES FOR THESE COMBINATIONS, WITH RESPECT TO SAFETY AND EFFICACY, HAVE NOT BEEN ESTABLISHED.', 'DELAVIRDINE', '\xe2\x86\x91 NELFINAVIR \xe2\x86\x93 DELAVIRDINE', 'NEVIRAPINE', '\xe2\x86\x93 NELFINAVIR (C MIN )', 'NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR: DIDANOSINE', '', 'IT IS RECOMMENDED THAT DIDANOSINE BE ADMINISTERED ON AN EMPTY STOMACH; THEREFORE, DIDANOSINE SHOULD BE GIVEN ONE HOUR BEFORE OR TWO HOURS AFTER VIRACEPT (GIVEN WITH FOOD).', '', 'PROTEASE INHIBITORS:', '', 'APPROPRIATE DOSES FOR THESE COMBINATIONS, WITH RESPECT TO SAFETY AND EFFICACY, HAVE NOT BEEN ESTABLISHED.', 'INDINAVIR', '\xe2\x86\x91 NELFINAVIR \xe2\x86\x91 INDINAVIR', 'RITONAVIR', '\xe2\x86\x91 NELFINAVIR', 'SAQUINAVIR', '\xe2\x86\x91 SAQUINAVIR', 'OTHER AGENTS', 'ANTI-COAGULANT: WARFARIN', 'WARFARIN', 'COADMINISTRATION OF WARFARIN AND VIRACEPT MAY AFFECT CONCENTRATIONS OF WARFARIN. IT IS RECOMMENDED THAT THE INR (INTERNATIONAL NORMALIZED RATIO) BE MONITORED CAREFULLY DURING TREATMENT WITH VIRACEPT, ESPECIALLY WHEN COMMENCING THERAPY.', 'ANTI-CONVULSANTS:', '', 'MAY DECREASE NELFINAVIR PLASMA CONCENTRATIONS. VIRACEPT MAY NOT BE EFFECTIVE DUE TO DECREASED NELFINAVIR PLASMA CONCENTRATIONS IN PATIENTS TAKING THESE AGENTS CONCOMITANTLY.', 'CARBAMAZEPINE PHENOBARBITAL', '\xe2\x86\x93 NELFINAVIR', 'ANTI-CONVULSANT:', '', 'PHENYTOIN PLASMA/SERUM CONCENTRATIONS SHOULD BE MONITORED; PHENYTOIN DOSE MAY REQUIRE ADJUSTMENT TO COMPENSATE FOR ALTERED PHENYTOIN CONCENTRATION.', 'PHENYTOIN', '\xe2\x86\x93 PHENYTOIN', 'ANTI-DEPRESSANT: TRAZODONE', '\xe2\x86\x91 TRAZODONE', 'CONCOMITANT USE OF TRAZODONE AND VIRACEPT MAY INCREASE PLASMA CONCENTRATIONS OF TRAZODONE. ADVERSE EVENTS OF NAUSEA, DIZZINESS, HYPOTENSION AND SYNCOPE HAVE BEEN OBSERVED FOLLOWING COADMINISTRATION OF TRAZODONE AND RITONAVIR. IF TRAZODONE IS USED WITH A CYP3A4 INHIBITOR SUCH AS VIRACEPT, THE COMBINATION SHOULD BE USED WITH CAUTION AND A LOWER DOSE OF TRAZODONE SHOULD BE CONSIDERED.', 'ANTI-GOUT COLCHICINE', '\xe2\x86\x91 COLCHICINE', 'TREATMENT OF GOUT FLARES\xe2\x80\x93 COADMINISTRATION OF COLCHICINE IN PATIENTS ON VIRACEPT: 0.6 MG (1 TABLET) \xc3\x97 1 DOSE, FOLLOWED BY 0.3 MG (HALF TABLET) 1 HOUR LATER. DOSE TO BE REPEATED NO EARLIER THAN 3 DAYS. PROPHYLAXIS OF GOUT-FLARES\xe2\x80\x93 COADMINISTRATION OF COLCHICINE IN PATIENTS ON VIRACEPT: IF THE ORIGINAL COLCHICINE REGIMEN WAS 0.6 MG TWICE A DAY, THE REGIMEN SHOULD BE ADJUSTED TO 0.3 MG ONCE A DAY. IF THE ORIGINAL COLCHICINE REGIMEN WAS 0.6 MG ONCE A DAY, THE REGIMEN SHOULD BE ADJUSTED TO 0.3 MG ONCE EVERY OTHER DAY. TREATMENT OF FAMILIAL MEDITERRANEAN FEVER (FMF)\xe2\x80\x93 COADMINISTRATION OF COLCHICINE IN PATIENTS ON VIRACEPT: MAXIMUM DAILY DOSE OF 0.6 MG (MAY BE GIVEN AS 0.3 MG TWICE A DAY). PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT SHOULD NOT BE GIVEN COLCHICINE WITH VIRACEPT.', 'ANTI-MYCOBACTERIAL:', '', 'IT IS RECOMMENDED THAT THE DOSE OF RIFABUTIN BE REDUCED TO ONE-HALF THE USUAL DOSE WHEN ADMINISTERED WITH VIRACEPT; 1250 MG BID IS THE PREFERRED DOSE OF VIRACEPT WHEN COADMINISTERED WITH RIFABUTIN.', 'RIFABUTIN', '\xe2\x86\x91 RIFABUTIN \xe2\x86\x93 NELFINAVIR (750 MG TID) \xe2\x86\x94 NELFINAVIR (1250 MG BID)', 'ENDOTHELIN RECEPTOR ANTAGONISTS: BOSENTAN', '\xe2\x86\x91 BOSENTAN', 'COADMINISTRATION OF BOSENTAN IN PATIENTS ON VIRACEPT OR COADMINISTRATION OF VIRACEPT IN PATIENTS ON BOSENTAN: START AT OR ADJUST BOSENTAN TO 62.5 MG ONCE DAILY OR EVERY OTHER DAY BASED UPON INDIVIDUAL TOLERABILITY.', 'HMG-COA REDUCTASE INHIBITOR:', '', 'USE LOWEST POSSIBLE DOSE OF ATORVASTATIN OR ROSUVASTATIN WITH CAREFUL MONITORING, OR CONSIDER OTHER HMG-COA REDUCTASE INHIBITORS SUCH AS PRAVASTATIN OR FLUVASTATIN IN COMBINATION WITH VIRACEPT.', 'ATORVASTATIN', '\xe2\x86\x91 ATORVASTATIN', 'ROSUVASTATIN', '\xe2\x86\x91 ROSUVASTATIN', 'IMMUNO-SUPPRESSANTS:', '', 'PLASMA CONCENTRATIONS MAY BE INCREASED BY VIRACEPT.', 'CYCLOSPORINE TACROLIMUS SIROLIMUS', '\xe2\x86\x91 IMMUNO-SUPPRESSANTS', 'INHALED BETA AGONIST: SALMETEROL', '\xe2\x86\x91 SALMETEROL', 'CONCURRENT ADMINISTRATION OF SALMETEROL WITH VIRACEPT IS NOT RECOMMENDED. THE COMBINATION MAY RESULT IN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS ASSOCIATED WITH SALMETEROL, INCLUDING QT PROLONGATION, PALPITATIONS AND SINUS TACHYCARDIA.', 'INHALED/NASAL STEROID: FLUTICASONE', '\xe2\x86\x91 FLUTICASONE', 'CONCOMITANT USE OF FLUTICASONE PROPIONATE AND VIRACEPT MAY INCREASE PLASMA CONCENTRATIONS OF FLUTICASONE PROPIONATE. USE WITH CAUTION. CONSIDER ALTERNATIVES TO FLUTICASONE PROPIONATE, PARTICULARLY FOR LONG-TERM USE.', 'MACROLIDE ANTIBIOTIC: AZITHROMYCIN', '\xe2\x86\x91 AZITHROMYCIN', 'DOSE ADJUSTMENT OF AZITHROMYCIN IS NOT RECOMMENDED, BUT CLOSE MONITORING FOR KNOWN SIDE EFFECTS SUCH AS LIVER ENZYME ABNORMALITIES AND HEARING IMPAIRMENT IS WARRANTED.', 'NARCOTIC ANALGESIC:', '', 'DOSAGE OF METHADONE MAY NEED TO BE INCREASED WHEN COADMINISTERED WITH VIRACEPT.', 'METHADONE', '\xe2\x86\x93 METHADONE', 'ORAL CONTRACEPTIVE:', '', 'ALTERNATIVE OR ADDITIONAL CONTRACEPTIVE MEASURES SHOULD BE USED WHEN ORAL CONTRACEPTIVES AND VIRACEPT ARE COADMINISTERED.', 'ETHINYL ESTRADIOL', '\xe2\x86\x93 ETHINYL ESTRADIOL', 'PDE5 INHIBITORS: SILDENAFIL VARDENAFIL TADALAFIL', '\xe2\x86\x91 PDE5 INHIBITORS', 'CONCOMITANT USE OF PDE5 INHIBITORS AND VIRACEPT SHOULD BE UNDERTAKEN WITH CAUTION. MAY RESULT IN AN INCREASE IN PDE5 INHIBITOR-ASSOCIATED ADVERSE EVENTS, INCLUDING HYPOTENSION, SYNCOPE, VISUAL DISTURBANCES, AND PRIAPISM. USE OF PDE-5 INHIBITORS FOR PULMONARY ARTERIAL HYPERTENSION (PAH): USE OF SILDENAFIL (REVATIO) IS CONTRAINDICATED WHEN USED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) [SEE CONTRAINDICATIONS ]. THE FOLLOWING DOSE ADJUSTMENTS ARE RECOMMENDED FOR USE OF TADALAFIL (ADCIRCA\xe2\x84\xa2) WITH VIRACEPT: COADMINISTRATION OF ADCIRCA IN PATIENTS ON VIRACEPT OR COADMINISTRATION OF VIRACEPT IN PATIENTS ON ADCIRCA: START AT OR ADJUST ADCIRCA TO 20 MG ONCE DAILY. INCREASE TO 40 MG ONCE DAILY BASED UPON INDIVIDUAL TOLERABILITY. USE OF PDE5 INHIBITORS FOR ERECTILE DYSFUNCTION: SILDENAFIL AT A SINGLE DOSE NOT EXCEEDING 25 MG IN 48 HOURS, VARDENAFIL AT A SINGLE DOSE NOT EXCEEDING 2.5 MG IN 24 HOURS, OR TADALAFIL AT A SINGLE DOSE NOT EXCEEDING 10 MG DOSE IN 72 HOURS, IS RECOMMENDED. USE WITH INCREASED MONITORING FOR ADVERSE EVENTS.']